Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michael Bettess"'
Publikováno v:
Immuno Oncology Insights. :69-71
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::351c55716e55c27c8c0fc6aad35aa5b5
https://doi.org/10.18609/ioi.2022.009
https://doi.org/10.18609/ioi.2022.009
Autor:
Michael Bettess, Simon Fisher, James S. Rush, Christopher Davis, Ian H. Frazer, Jonathan B. Baell, Michael P. Brown, Mark Sullivan, Michael P. Jennings, Michael A. McGuckin, Eloise Keeffe, Craig Rayner, Anand Gautam, Philip Kearney, C. Glenn Begley, Brett Carter, William N. Charman, Michael W. Parker, Mark R. Ashton, Brett Roberts, Angel F. Lopez, Darren J. Kelly
Publikováno v:
Science translational medicine. 13(612)
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often, however, there is insufficient consideration by academic researchers of the processes required to ensure that a repurposed drug can be used for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11fd4678be2e05d0047237accbbe9583
https://pubmed.ncbi.nlm.nih.gov/34550729
https://pubmed.ncbi.nlm.nih.gov/34550729
Autor:
Anna V. Galkin, Francesca Mercuri, Nicholas West, Ping Zhang, Weiguang Zeng, Grant McLachlan, Michael Bettess, Ian Holmes, David Jackson, Chris Smith, Christophe Demaison, Tobias Bald, Phil Kearney
Publikováno v:
Cancer Research. 82:3502-3502
Background: Treatment approaches that engage both the innate and adaptive immune response have the potential to transform anti-cancer therapy, especially in settings of checkpoint inhibitor insensitivity or acquired resistance. Toll-like receptors (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7070b1f0f5dbd85b0f8944717eef2be2
https://doi.org/10.1158/1538-7445.am2022-3502
https://doi.org/10.1158/1538-7445.am2022-3502